HIF1A and cancer: Compounds that disrupt HIF signaling pathways, including HIF-1α inhibitors and prolyl hydroxylase inhibitors, have demonstrated potential in preclinical research by effectively suppressing HIF-mediated autophagy and improving the effectiveness of standard cancer treatments [9].